Cited 0 time in
Polymeric Systems for Cancer Immunotherapy: A Review
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Le, Thai Minh Duy | - |
| dc.contributor.author | Yoon, A-Rum | - |
| dc.contributor.author | Thambi, Thavasyappan | - |
| dc.contributor.author | Yun, Chae-Ok | - |
| dc.date.accessioned | 2022-07-06T10:14:29Z | - |
| dc.date.available | 2022-07-06T10:14:29Z | - |
| dc.date.created | 2022-04-06 | - |
| dc.date.issued | 2022-02 | - |
| dc.identifier.issn | 1664-3224 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/139490 | - |
| dc.description.abstract | Immunotherapy holds enormous promise to create a new outlook of cancer therapy by eliminating tumors via activation of the immune system. In immunotherapy, polymeric systems play a significant role in improving antitumor efficacy and safety profile. Polymeric systems possess many favorable properties, including magnificent biocompatibility and biodegradability, structural and component diversity, easy and controllable fabrication, and high loading capacity for immune-related substances. These properties allow polymeric systems to perform multiple functions in immunotherapy, such as immune stimulants, modifying and activating T cells, delivery system for immune cargos, or as an artificial antigen-presenting cell. Among diverse immunotherapies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T cell, and oncolytic virus recently have been dramatically investigated for their remarkable success in clinical trials. In this report, we review the monotherapy status of immune checkpoint inhibitors, CAR-T cell, and oncolytic virus, and their current combination strategies with diverse polymeric systems. | - |
| dc.language | 영어 | - |
| dc.language.iso | en | - |
| dc.publisher | FRONTIERS MEDIA SA | - |
| dc.title | Polymeric Systems for Cancer Immunotherapy: A Review | - |
| dc.type | Article | - |
| dc.contributor.affiliatedAuthor | Yun, Chae-Ok | - |
| dc.identifier.doi | 10.3389/fimmu.2022.826876 | - |
| dc.identifier.scopusid | 2-s2.0-85126040256 | - |
| dc.identifier.wosid | 000769804700001 | - |
| dc.identifier.bibliographicCitation | FRONTIERS IN IMMUNOLOGY, v.13, pp.1 - 22 | - |
| dc.relation.isPartOf | FRONTIERS IN IMMUNOLOGY | - |
| dc.citation.title | FRONTIERS IN IMMUNOLOGY | - |
| dc.citation.volume | 13 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 22 | - |
| dc.type.rims | ART | - |
| dc.type.docType | Review | - |
| dc.description.journalClass | 1 | - |
| dc.description.isOpenAccess | N | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Immunology | - |
| dc.relation.journalWebOfScienceCategory | Immunology | - |
| dc.subject.keywordPlus | ANTIGEN-PRESENTING CELLS | - |
| dc.subject.keywordPlus | MEDIATED GENE-TRANSFER | - |
| dc.subject.keywordPlus | IMMUNE CHECKPOINT INHIBITORS | - |
| dc.subject.keywordPlus | LARGE MULTIVALENT IMMUNOGEN | - |
| dc.subject.keywordPlus | SYNTHETIC DENDRITIC CELLS | - |
| dc.subject.keywordPlus | VACCINE DELIVERY-SYSTEM | - |
| dc.subject.keywordPlus | EFFICIENT IN-VITRO | - |
| dc.subject.keywordPlus | CD8(+) T-CELLS | - |
| dc.subject.keywordPlus | ONCOLYTIC ADENOVIRUS | - |
| dc.subject.keywordPlus | DRUG-DELIVERY | - |
| dc.subject.keywordAuthor | immune checkpoint inhibitor | - |
| dc.subject.keywordAuthor | immunotherapy | - |
| dc.subject.keywordAuthor | polymeric system | - |
| dc.subject.keywordAuthor | oncolytic adenovirus | - |
| dc.subject.keywordAuthor | CAR-T cell | - |
| dc.identifier.url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.826876/full | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
